Correction of IVS I-110(G>A) β-thalassemia by CRISPR/Cas- and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells

Petros Patsali, Giandomenico Turchiano, Panayiota Papasavva, Marianna Romito, Constantinos C. Loucari, Coralea Stephanou, Soteroulla Christou, Maria Sitarou, Claudio Mussolino, Tatjana I. Cornu, Michael N. Antoniou, Carsten W. Lederer, Toni Cathomen, and Marina Kleanthous

Disclosures: T.C. is a consultant for TRACR Hematology. Research in the laboratories of C.M., T.I.C. and T.C. is supported by Casebia Therapeutics, Cellectis S.A. and Miltenyi Biotec. There are no other conflicts of interest to declare for any of the authors.

Contributions: P. Patsali performed molecular and cell culture work, designed, cloned and produced molecular tools, performed bioinformatics analyses and prepared all figures and the initial manuscript draft. G.T. assisted with nucleofections and performed deep sequencing experimentation and related scoring. M.R. assisted with T7E1 assays and prepared TALEN mRNAs. P. Papasavva, performed cell culture work and scored cytocentrifugation samples. C.C.L. assisted in RNP preparation. C.S. assisted with lentiviral constructs. S.C. and M.S. coordinated sampling and hematological analyses. C.M. designed molecular tools and guided study design. M.N.A. guided study design and progress. T.I.C. supervised mRNA production. C.W.L. wrote the grants, conceived and supervised the study, performed HPLC analyses and wrote the manuscript. T.C. hosted the research and guided study design. M.K. hosted the research and guided study design. P. Patsali, P. Papasavva, C.S., C.M., T.I.C., M.N.A., C.W.L., T.C. and M.K. contributed to the final version of the manuscript. All authors have approved the final version of the article. The present work has not been published previously and is not under consideration for publication elsewhere. No third-party writing or editing services were used in the creation of this manuscript.